Overview of Daktarin 2%

Property	Description
Active ingredient	Miconazole Nitrate
Form	Topical Cream (2%)
Pharmacological class	Antifungal (Azole derivative)
Common use	Resolution of fungal and yeast skin infections
Origin	Synthetic

Daktarin 2% is a synthetic topical medicine used to address superficial fungal skin infections due to its active ingredient, Miconazole Nitrate. It is officially classified as an Antifungal agent within the Azole derivative family, a classification clinically recognized for treating a wide spectrum of fungal pathogens.

What Type of Medicine is Daktarin 2%?

Daktarin 2% is an antifungal medication that falls under the Azole derivative pharmacological class, a group of agents well-characterized by their specific mechanism of action against fungi. Its active component, Miconazole Nitrate, is a synthetic compound whose efficacy has been reliably supported by decades of clinical application. This classification dictates that the medicine's primary role is to eliminate or suppress the growth of fungal pathogens. The substance is documented as possessing a broad spectrum of activity, including against dermatophytes and yeasts, as confirmed by regulatory review.

Composition and Form: What is Miconazole Nitrate Cream?

This medicine is provided as a topical cream containing Miconazole Nitrate at a concentration of 2%. The formulation utilizes an emulsion base specifically designed for dermal application, which means the medicine is intended for direct contact with the affected skin surface. Miconazole Nitrate is further recognized for its dual functionality, possessing not only strong antifungal action but also exhibiting an effect against certain Gram-positive bacteria often associated with mixed infections. The cream form, unlike powders or sprays, offers an emollient vehicle suitable for application to dry or inflamed skin.

What is the General Purpose of This Topical Antifungal?

The general purpose of this topical preparation is to promote the resolution of infections by stopping the proliferation and survival of fungi on the skin. Miconazole Nitrate achieves this by interfering with the fungal cell membrane; specifically, it inhibits the synthesis of ergosterol, a vital component required for the cell to maintain its structural integrity. This targeted cellular disruption is the key to its function in treating typical superficial skin infections. By impairing the fungus's ability to survive and spread, the medicine helps the body overcome the infection.

Regulatory References

Miconazole Topical: MedlinePlus Drug Information

What side effects are possible with Daktarin 2%?

Possible Side Effects and Safety Information

The safety profile of Miconazole Nitrate Topical Cream is formally categorized based on regulatory documents and is structured around the incidence of adverse reactions.

Adverse Reaction Scope

The most frequently reported adverse reactions are localized dermatological effects at the site of application. These reactions are classified as Common in regulatory frequency tables and may include a burning sensation, skin irritation, and pruritus (itching). Official labeling notes that these local effects are often observed at the initiation of treatment.

Systemic and Serious Reactions

The regulatory safety profile also includes the possibility of rare but clinically significant systemic reactions. These include Hypersensitivity Reactions, which are classified with a frequency of Not Known (cannot be estimated from available data) and may manifest as severe allergic responses such as Angioedema or Urticaria (hives). Reactions that affect the Immune system disorders and Skin and Subcutaneous Tissue Disorders are formally grouped in official safety documentation.

Safety Considerations

The labeling includes constraints regarding potential systemic absorption, even though it is typically minimal following dermal application. A specific safety statement addresses the potential for drug-drug interaction with certain oral anticoagulants (e.g., warfarin), which may be associated with an increased bleeding risk. Furthermore, formal safety notes are documented regarding the potential use during Pregnancy and Lactation, due to the need to consider any systemic exposure, however low.

Overdose and Emergency Response

The official overdose profile for Miconazole Nitrate 2% Topical Cream is based on two primary scenarios: risks associated with excessive topical use and potential effects from accidental oral ingestion, given the product's minimal systemic absorption.

Overdose Scenarios

Excessive application to the skin may result in localized manifestations, including skin irritation, which regulatory labeling documents as redness, swelling, or a burning sensation. The official procedural guidance for this localized overdose is to temporarily stop or reduce the frequency of application until irritation subsides.

The primary systemic risk documented in official materials arises from the accidental swallowing of a large quantity of the cream. Ingestion may cause gastric trouble or other gastrointestinal disturbances.

When to Seek Urgent Help

Immediate medical help must be sought if the cream is swallowed. Regulatory agencies mandate that users contact a Poison Control Center or seek medical attention right away for this circumstance. Treatment in such cases is limited to appropriate symptomatic and supportive care, as regulatory documents state that no specific antidote is known for this product. The official profile does not detail population-specific overdose severity notes for children or the elderly.

Therapeutic Uses of Daktarin 2%

What Daktarin 2% Treats: Main Uses and Benefits

The core therapeutic domains of Daktarin 2% are applied in addressing various skin infections and providing symptomatic relief. This medicine is relevant for helping to ease symptoms related to common conditions. It is commonly used across conditions presenting with acute or disruptive episodes, including athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

Targeting Discomfort and Irritation

Daktarin 2% is relevant in contexts marked by increased discomfort or tension related to the infection. It is commonly used to help with symptoms related to inflammatory or irritative states, such as itching, scaling, burning, and soreness. It is applied in situations involving certain distressing symptoms where groups of symptoms appear suddenly or fluctuate. This offers symptomatic support that helps patients cope more steadily during difficult symptomatic periods.

“It provides support that helps ease the overall symptom burden, assisting with maintaining functional stability.”

Quick Fact: Relief for Itching and Burning

Daktarin 2% may support the patient during episodes of heightened discomfort by easing the symptom load associated with common fungal skin conditions.

Regulatory References

Health Canada Labelling Standard for Miconazole

Eligibility and Restrictions for Use

The official regulatory documents define clear eligibility and non-eligibility rules for the use of Miconazole Nitrate 2% Cream.

Populations for Whom Use is Contraindicated

Classification	Population Group/Condition
Absolute Contraindication	Patients with known hypersensitivity to the active substance (Miconazole Nitrate), other imidazole derivatives, or any excipients.

Age-Related Eligibility Rules

Age Group	Regulatory Status
Children under 2 years	Not recommended for use unless specifically directed by a doctor (US OTC labeling).
Newborn babies (up to 4 weeks)	Use is restricted due to a regulatory warning concerning the excipient Benzoic acid, which may potentially increase jaundice.
The Elderly	No data available on use in the elderly (regulatory statement indicating insufficient clinical data).

Conditional Use and Restrictions

Physiological State/Comorbidity	Eligibility Status
Pregnancy and Lactation	Use should be approached with caution, as stated in the product information.
Concurrent Oral Anticoagulants	Caution should be exercised; anticoagulant effect (e.g., of warfarin) must be closely monitored due to potential drug interaction (Systemic absorption) documented in regulatory warnings.

The regulatory profile establishes eligibility by defining a primary non-use criterion: allergy to the drug or related antifungals. Beyond this, use is restricted or conditional in specific demographics, particularly newborns and young children, and during pregnancy and lactation. A key eligibility restriction requires special monitoring for patients taking oral anticoagulants, reflecting official safety warnings regarding potential systemic effect.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Miconazole Nitrate topical cream is primarily structured around the potential for the substance to inhibit certain metabolic enzymes, specifically CYP3A4 and CYP2C9. This interaction mechanism is recognized by regulatory authorities, although the clinical relevance is generally considered low due to the limited systemic absorption of the topical formulation.

Documented Pharmacokinetic Interaction Profile

Co-administration with Daktarin 2% may lead to a pharmacokinetic enhancement of the following drug categories and specific medicines, potentially increasing their effects and side effects:

Oral Anticoagulants (Vitamin K antagonists): Such as Warfarin. Regulatory documents advise that co-administration may enhance the anticoagulant effect and mandate specific monitoring of the patient's International Normalized Ratio (INR).
Oral Hypoglycemics: Medicines in the sulfonylurea class, including Glibenclamide and Gliclazide.
Anticonvulsants: Such as Phenytoin.

Restrictions and Classification

Regulatory sources classify these as Use with Caution interactions. The official labeling for the topical cream does not list any formal drug-drug contraindications that strictly prohibit co-administration. Furthermore, there are no mandatory regulatory statements requiring dose timing separation or restrictions related to food, alcohol, or herbal products.

Mechanism of Action

Targeting the Fungal Cell's Structural Foundation

Miconazole functions as a specific enzyme inhibitor within the microbial cell. Its primary mechanistic domain involves the inhibition of lanosterol 14alpha-demethylase (CYP51), an enzyme essential for creating ergosterol. This blockade destabilizes the Sterol Biosynthesis Pathway, which synthesizes essential fungal membrane components.

Pathway Disruption and Membrane Failure

The failure to synthesize ergosterol causes the fungal cell membrane to lose its integrity, fluidity, and stability. This molecular cascade leads to the accumulation of toxic sterols and increased permeability, resulting in the fungistatic consequence (arrested growth) and, depending on local concentration, the fungicidal consequence (cellular breakdown). This mechanism is further supplemented by a secondary action where Miconazole directly damages the cell walls of susceptible Gram-positive bacteria, affecting the structural integrity of these organisms.

Dosage and Administration Information

How Daktarin 2% is Used: Official Administration Guidelines

The usage of Miconazole Nitrate 2% Cream follows specific parameters outlining the administration route, application method, and treatment duration patterns. This standardized protocol ensures the medicine is used consistently.

Administration Scope

Parameter	Official Instruction
Route of Administration	Topical (Cutaneous) application only.
Dosing Schedule	Apply a thin layer sufficient to cover the affected skin area and the immediate surrounding skin.
Frequency and Timing	Twice daily (typically morning and evening).
Preparation Requirements	The affected skin area must be cleaned and dried thoroughly before application.
Age-Group Administration	Children under 2 years of age: Do not use unless explicitly directed by a healthcare professional.
Missed-Dose Rule	Apply the cream as soon as it is remembered; do not apply a double quantity to compensate for a missed application.
Special Procedural Condition	Treatment should be continued for at least one week after the disappearance of all signs and symptoms to discourage recurrence.

Course Duration and Use Context

The required duration of use is dependent on the type of infection, defining a time-bound course of treatment.

Condition	Standard Labeled Duration
Jock Itch (Tinea cruris)	Typically 2 weeks.
Athlete’s Foot (Tinea pedis)	Typically 4 weeks.
Ringworm (Tinea corporis)	Typically 4 weeks.

Resulting Procedural Structure

The official administration protocol mandates that the affected area first be cleaned and dried thoroughly. A thin layer of the cream is then applied and rubbed into the skin twice daily. The total duration of use is pre-defined based on the infection, but requires continuation for a period past symptom clearance. The medicine is not effective for fungal infections of the scalp or nails and is strictly for external use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Daktarin 2%

This section describes the types of clinical evaluations and research that Miconazole Nitrate 2% cream (Daktarin 2%) was studied for, and what patterns have been observed in the available data. It is an overview of the research and should not be used for personal medical advice.

Evidence for Use in Tinea Pedis (Athlete's Foot)

The research base for Miconazole Nitrate 2% cream in athlete's foot (Tinea pedis) includes clinical evaluation spanning several decades, primarily consisting of Randomized Controlled Trials (RCTs). These RCTs compare the medicine to a non-medicated cream (vehicle) or to other similar topical antifungal agents. Studies monitored two main outcomes: Mycological Cure, which is defined in trials as the laboratory absence of the fungus, and Clinical Cure, which is defined as the assessment of changes in visible symptoms such as itching and scaling. The general adult population was evaluated in these studies.

Research has explored whether studies comparing the cream to a non-medicated vehicle described patterns related to the achievement of Mycological Cure and changes in symptoms. The trials reported group patterns related to these outcomes, often over a short-term treatment period typically lasting two to four weeks. Evidence suggests that the medicine was observed in trials that track the assessment of symptoms over this defined time interval.

Evidence for Use in Tinea Cruris (Jock Itch) and Tinea Corporis (Ringworm)

For tinea infections of the body (Tinea corporis) and groin (Tinea cruris), the evidence base includes numerous RCTs and comparative trials. These studies explored how symptoms were recorded in the observed populations with laboratory-confirmed fungal infections. The research examined outcomes related to the change in lesions and outcomes linked to inflammatory or irritative states, such as redness and itching. Studies monitored the proportion of patients where a mycological cure was observed in the study populations following the designated treatment phase.

Data for certain groups remain insufficient. For instance, evidence derived from settings with varying symptom burdens is less clear for individuals with severe, extensive infections. The studies primarily focused on short-term symptom changes during treatment phases that often last around three to four weeks, and long-term effects are not fully established regarding relapse prevention over several months.

Research Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain—about this medicine. A primary gap is the lack of extensive, standardized data on long-term outcomes. While short-term outcomes were recorded, the durability of the outcome over six months or more is not fully established across all indications.

Research also describes instances where evidence quality varies across studies due to modest sample sizes in older trials or heterogeneity in trial design. Finally, comparative evidence is lacking for some of the newer, alternative antifungal agents against Miconazole in large-scale RCTs, as much of the recent work compares it to other existing treatments.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Daktarin 2% (FAQ)

Q: Can Daktarin 2% cream also treat associated bacterial infections?

Official product information notes that the active ingredient, Miconazole Nitrate, is documented to possess activity against some of the Gram-positive bacteria that may be present alongside a fungal skin infection. However, its primary intended use remains the treatment of the fungal component.

Q: What are the signs of a more severe allergic reaction to Daktarin 2% that require stopping use?

Severe allergic reactions, although rare, have been reported in official safety profiles. Signs that may indicate a serious reaction, such as angioedema (swelling) or anaphylaxis, include swelling of the face, lips, tongue, or throat, or having difficulty breathing. If any of these signs occur, it is a serious event noted in regulatory documents, and medical assistance should be sought.

Q: What should be done if Daktarin 2% is accidentally swallowed?

In the event of accidental ingestion, official regulatory warnings indicate that medical help or contact with a Poison Control Center should be sought. Furthermore, regulatory documents note that using the cream on the skin in excessive amounts can cause local irritation, but this typically resolves once the application is stopped.

Q: Are there any other topical products (creams, ointments) that should be avoided while using Daktarin 2%?

Official labeling does not list formal contraindications for other topical products. However, regulatory documents contain a safety note concerning the potential for Miconazole to damage the latex material used in barrier contraceptives (such as condoms or diaphragms) if the medicine is applied to the genital area.

Q: What is the risk of reinfection if the full course of treatment is not completed?

The official administration guidelines emphasize the importance of completing the full course of therapy. Regulatory instructions recommend continuing to apply the cream for a period (typically at least one week) after all signs and symptoms have disappeared. This is done to help discourage the recurrence or return of the fungal infection.

Q: Is Daktarin 2% available over-the-counter or does it always require a prescription?

In many regions, Miconazole Nitrate 2% cream is classified by health authorities as an Over-The-Counter (OTC) medicine. This classification indicates that it is widely available for the self-treatment of common fungal skin infections without requiring a prescription.

Q: If Daktarin 2% is used on the foot, is it safe to use it on the hand to treat another infection?

The product is intended for topical use on the affected skin area. Regulatory guidance stresses the importance of washing your hands carefully after each application. This procedural step helps prevent the unintentional spread of the fungal infection to other body parts.

Q: Can I use Daktarin 2% for dandruff (seborrheic dermatitis)?

The medicine is officially indicated for the treatment of Athlete's Foot, Jock Itch, Ringworm, and skin yeast infections. Official product information explicitly states that the cream formulation is not effective for fungal infections of the scalp, which would include most cases of dandruff.

Q: What precautions should be taken when using Daktarin 2% on an infected area that is covered by clothes or a dressing?

Official safety warnings highlight a serious fire hazard when using this cream. Fabric (including clothing, bedding, and dressings) that has been in contact with Miconazole cream is a fire risk, as it burns more easily. Official safety warnings note the need to avoid smoking or going near naked flames while the product is on the skin or clothes.

Q: Is it normal for the infected skin to look dry or flaky while using Daktarin 2%?

Clinical trials often assess treatment success by monitoring changes in visible symptoms, such as scaling and flaking. The official evidence suggests that the presence of these symptoms may be part of the healing process as the infection resolves and damaged skin sheds.

Q: Does Daktarin 2% provide moisturizing effects as well as antifungal action?

Yes, official product descriptions note that the cream is formulated as an emollient vehicle. This means the base of the cream is designed to help soothe dry, cracked, and red skin while the active ingredient provides the necessary antifungal treatment.

Q: Is there a maximum number of days/weeks Daktarin 2% can be safely used continuously?

The official duration of therapy is clearly defined based on the specific infection being treated. Official regulatory guidance indicates that the medicine is not recommended for use beyond the specified duration for the infection type, plus the suggested follow-up period, unless a healthcare professional has been consulted.

Q: Does Daktarin 2% require special disposal instructions once the treatment is finished?

Yes, regulatory documents specify that unused medicinal product or waste material should not be disposed of via household waste or wastewater (drains). You should consult a pharmacist or local authority for instructions on the safe disposal of pharmaceutical waste.

Q: Can Daktarin 2% be used on the outer ear for a fungal infection?

Official product information states that Miconazole cream is used for the treatment of fungal infections of the skin. This would include infections that appear on the skin of the outer ear.

Q: What is the difference in treatment approach for a cutaneous candidiasis versus a dermatophyte infection with Daktarin 2%?

The official duration of treatment with Miconazole 2% cream is determined by the type of infection being treated. The standard course can vary depending on the specific fungal organism and body location, ranging from two to six weeks. Therefore, the duration of use is often the primary difference in the treatment approach.

How should Daktarin 2% be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Daktarin 2% Cream must adhere strictly to regulatory guidelines to maintain product stability and safety.

Requirement Area	Official Instructions
Temperature Control	Do not store the cream above 25 C.
Environment	Keep the tube in a cool, dry place, protected from moisture.
Packaging	Do not use the product after the expiry date (EXP), and do not use if the tube's seal is damaged.
Child Safety	KEEP OUT OF REACH OF CHILDREN at all times.
Disposal	Do not dispose of unused or expired product via household waste or wastewater (drains). Consult a pharmacist or local authorities for instructions on disposal of pharmaceutical waste.

Daktarin 2%